Vaxart, Inc. — Form 8-K
Filed July 7, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Vaxart reported 12-month safety data from a 400-participant sentinel cohort (201 oral pill, 199 mRNA comparator) of its Phase 2b COVID-19 vaccine trial. No vaccine-related serious adverse events or sustained Grade 3+ adverse events were reported in either arm; oral pill showed lower AE rates (malaise/fatigue 20.9%, headache 18.9%) versus mRNA (injection site pain 60.3%, myalgia 33.2%). Complete study results from ~5,400 total participants expected in 2027; trial is funded by BARDA/NIAID under a $344.8M Project NextGen award.
Why this rating
Positive safety data advances pipeline; $344.8M government funding is 3.4× market cap. However, efficacy unproven (33 vs 30 symptomatic cases, underpowered), main results delayed to 2027, and regulatory approval uncertain. Material but pre-commercial stage.
See more from July 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.